<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35386024</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-3524</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurotoxicity research</Title>
          <ISOAbbreviation>Neurotox Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Effect of Glutathione Deficit During Early Postnatal Brain Development on the Prepulse Inhibition and Monoamine Levels in Brain Structures of Adult Sprague-Dawley Rats.</ArticleTitle>
        <Pagination>
          <StartPage>733</StartPage>
          <EndPage>750</EndPage>
          <MedlinePgn>733-750</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12640-022-00496-5</ELocationID>
        <Abstract>
          <AbstractText>Recent studies suggest that impaired glutathione synthesis and distorted dopaminergic transmission are important factors in the pathophysiology of schizophrenia. In the present study, on the postnatal days p5-p16, male pups were treated with the inhibitor of glutathione synthesis, L-buthionine-(S,R)- sulfoximine (BSO, 3.8 or 7.6 mmol/kg), and the dopamine uptake inhibitor, GBR 12,909 (5 mg/kg) alone or in combination, and prepulse inhibition of the acoustic startle response (PPI) was evaluated in adult 90-day-old rats. Moreover, the monoamine levels in the cortex and hippocampus of 16-day-old rats or 91-day-old rats were measured. The present results showed that administration of BSO at 3.8 mmol/kg led to a decreasing tendency in PPI for all tested prepulse intensities. In contrast, a combined treatment with BSO in both studied doses and GBR 12,909 did not induce significant deficits in PPI. Moreover, the results of biochemical studies indicated that treatment with BSO or GBR 12,909 alone induced a weak increase in the activity of dopaminergic, serotonergic, and noradrenergic systems in the frontal cortex and hippocampus of 16-day-old rats and 91-day-old rats. However, the combined administration of both substances allowed for maintaining the normal activity of monoaminergic systems in the rat brain. The most significant changes in the functioning of monoaminergic systems were observed in the frontal cortex of 16-day-old rats. Therefore, it seems that the frontal cortex of rat puppies is most sensitive to glutathione deficiencies resulting in increased oxidative stress in neurons. As a result, it can lead to cognitive and memory impairment.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rogóż</LastName>
            <ForeName>Zofia</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lech</LastName>
            <ForeName>Marta A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chamera</LastName>
            <ForeName>Katarzyna</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology Polish Academy of Sciences, 12 Smętna Street, Kraków, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wąsik</LastName>
            <ForeName>Agnieszka</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3772-0688</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurochemistry, Maj Institute of Pharmacology Polish Academy of Sciences, 12 Smętna Street, Kraków, Poland. wasik@if-pan.krakow.pl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurotox Res</MedlineTA>
        <NlmUniqueID>100929017</NlmUniqueID>
        <ISSNLinking>1029-8428</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VTD58H1Z2X</RegistryNumber>
          <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065808" MajorTopicYN="Y">Prepulse Inhibition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013216" MajorTopicYN="Y">Reflex, Startle</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Animal model of schizophrenia</Keyword>
        <Keyword MajorTopicYN="N">Brain monoamine levels</Keyword>
        <Keyword MajorTopicYN="N">GBR 12,909</Keyword>
        <Keyword MajorTopicYN="N">Glutathione deficiency</Keyword>
        <Keyword MajorTopicYN="N">L-Butionine-(S,R)-sulfoximine (BSO)</Keyword>
        <Keyword MajorTopicYN="N">Prepulse inhibition test (PPI)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35386024</ArticleId>
        <ArticleId IdType="doi">10.1007/s12640-022-00496-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s12640-022-00496-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Arnsten AF (1997) Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11:151–162</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/026988119701100208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Białoń M, Żarnowska M, Antkiewicz-Michaluk L, Wąsik A (2020) Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects. Psychopharmacology 237(6):1577–1593. https://doi.org/10.1007/s00213-020-05484-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-020-05484-1</ArticleId>
            <ArticleId IdType="pubmed">32076746</ArticleId>
            <ArticleId IdType="pmc">7239818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bitanihirwe BK, Woo TU (2011) Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 35:878–893. https://doi.org/10.1016/j.neubiorev.2010.10.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2010.10.008</ArticleId>
            <ArticleId IdType="pubmed">20974172</ArticleId>
            <ArticleId IdType="pmc">3021756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabungcal JH, Nicolas D, Kraftsik R, Cuénod M, Do KQ, Hornung J-P (2006) Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis 22:624–637. https://doi.org/10.1016/j.nbd.2006.01.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2006.01.003</ArticleId>
            <ArticleId IdType="pubmed">16481179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabungcal JH, Preissmann D, Delseth C, Cuénod M, Do KQ, Schenk F (2007) Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats. Relevance to Schizophrenia. Neurobiol Dis 26:634–645. https://doi.org/10.1016/j.nbd.2007.03.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2007.03.001</ArticleId>
            <ArticleId IdType="pubmed">17459716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castagné V, Cuenod M, Do KQ (2004a) An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience 123:821–834. https://doi.org/10.1016/j.neuroscience.2003.11.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2003.11.012</ArticleId>
            <ArticleId IdType="pubmed">14751276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castagné V, Rougemont M, Cuenod M, Do KQ (2004b) Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat’s development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis 15:93–105. https://doi.org/10.1016/j.nbd.2003.09.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2003.09.005</ArticleId>
            <ArticleId IdType="pubmed">14751774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamera K, Szuster-Głuszczak M, Trojan E, Basta-Kaim A (2020) Maternal immune activation sensitizes male offspring rats to lipopolysaccharide-induced microglial deficits involving the dysfunction of CD200-CD200R and CX3CL1-CX3CR1 systems. Cells 9(7):1676. https://doi.org/10.3390/cells9071676</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9071676</ArticleId>
            <ArticleId IdType="pmc">7407118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148(11):1476–1486</Citation>
        </Reference>
        <Reference>
          <Citation>De Queiroz AIG, Chaves Filho AJM, da Silva Araújo T, Lima CNC, Machado MDJS, Carvalho AF, Vasconcelos SMM, de Lucena DF, Quevedo J, Macedo D (2018) Antimanic activity of minocycline in a GBR12909-induced model of mania in mice: Possible role of antioxidant and neurotrophic mechanisms. J Affect Disord 225:40–51. https://doi.org/10.1016/j.jad.2017.07.053</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jad.2017.07.053</ArticleId>
            <ArticleId IdType="pubmed">28783519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M (2009) Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19:220–230. https://doi.org/10.1016/j.conb.2009.05.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.conb.2009.05.001</ArticleId>
            <ArticleId IdType="pubmed">19481443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12:3721–3728. https://doi.org/10.1046/j.1460-9568.2000.00229.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1460-9568.2000.00229.x</ArticleId>
            <ArticleId IdType="pubmed">11029642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncan EJ, Szilagyi S, Efferen TR, Schwartz MP, Parwani A, Chakravorty S, Madonick SH, Kunzova A, Harmon JW, Angrist B, Gonzenbach S, Rotrosen JP (2003) Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia. Psychopharmacology 167:63–71</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-002-1372-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT (2011) Decreased levels of gluthatione, the major brain antioxidant, in post- mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 14:123–130. https://doi.org/10.1017/S1461145710000805</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1461145710000805</ArticleId>
            <ArticleId IdType="pubmed">20633320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geyer MA, Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1071–1079. https://doi.org/10.1016/j.pnpbp.2003.09.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pnpbp.2003.09.003</ArticleId>
            <ArticleId IdType="pubmed">14642967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117–154</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s002130100811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldner EM, Hsu L, Waraich P, Somers JM (2002) Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 47:833–843</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/070674370204700904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Górny M, Bilska-Wilkosz A, Iciek M, Hereta M, Kamińska K, Chwatko G, Rogóż Z, Lorenc-Koci E (2020) Alterations in the antioxidant enzymes activities in the neurodevelopmental rat model of schizophrenia induced by glutathione deficiency during early postnatal lift. Antioxidants (basil) 9:538. https://doi.org/10.3390/antiox9060538</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/antiox9060538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Górny M, Wnuk A, Kamińska A, Kamińska K, Chwatko G, Bilska-Wilkosz A, Iciek M, Kajta M, Rogóż Z, Lorenc-Koci E (2019) Glutathione deficiency and alternations in the sulfur amino acid homeostasis during early postnatal development as potential triggering factor for schizophrenia- like behavior in adult rats. Molecules 24(23):4253. https://doi.org/10.3390/molecules242342532</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules242342532</ArticleId>
            <ArticleId IdType="pmc">6930621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graeff FG, Guimarães FS, De Andrade TG, Deakin JF (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54(1):129–141</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0091-3057(95)02135-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inagaki T, Gautreaux C, Luine V (2010) Acute estrogen treatment facilitates recognition memory consolidation and alters monoamine levels in memory-related brain areas. Horm Behav 58:415–426. https://doi.org/10.1016/j.yhbeh.2010.05.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yhbeh.2010.05.013</ArticleId>
            <ArticleId IdType="pubmed">20553724</ArticleId>
            <ArticleId IdType="pmc">2917540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lech MA, Leśkiewicz M, Kamińska K, Rogóż Z, Lorenc-Koci E (2021) Glutathione deficiency during elary postnatal development caused schizophrenia-like symptoms and a reduction in BDNF levels in the cortex and hippocampus of adult Sprague-Dawley rats. Int J Mol Sci 22:6171. https://doi.org/10.3390/ijm22126171</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijm22126171</ArticleId>
            <ArticleId IdType="pubmed">34201038</ArticleId>
            <ArticleId IdType="pmc">8229148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis DA, Lieberman JA (2000) Caching up on schizophrenia: natural history and neurobiology. Neuron 28:325–334</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0896-6273(00)00111-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorenc-Koci E (2015) Dysregulation of glutathione synthesis in psychiatric disorders. In: Studies on psychiatric disorders. Oxidative stress in applied basic research and clinical practice. Eds. Dietrich-Muszalska A, Chauhan V, Grignon S, Humana Press, pp 269–299</Citation>
        </Reference>
        <Reference>
          <Citation>Mäki-Marttunen V, Andreassen OA, Espeseth T (2020) The role of norepinephrine in the pathophysiology of schizophrenia. Neurosci Biobehav Rev 118:298–314. https://doi.org/10.1016/j.neubiorev.2020.07.038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2020.07.038</ArticleId>
            <ArticleId IdType="pubmed">32768486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mena A, Ruiz-Salas JC, Puentes A, Dorado I, Ruiz-Veguilla M (2016) De la Casa LG (2016) Reduced prepulse inhibition as a biomarker of schizophrenia. Front Behav Neurosci 18(10):202. https://doi.org/10.3389/fnbeh.2016.00202</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnbeh.2016.00202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moriwaki M, Kishi T, Takahashi H, Hashimoto R, Kawashima K, Okochi T, Kitajima T, Furukawa O, Fujita K, Takeda M, Iwata N (2009) Prepulse inhibition of the startle response with chronic schizophrenia: a replication study. Neurosci Res 65(3):259–262. https://doi.org/10.1016/j.neures.2009.07.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neures.2009.07.009</ArticleId>
            <ArticleId IdType="pubmed">19660506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuechterlein KH, Barch DM, Gold JM et al (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29–39. https://doi.org/10.1016/j.schres.2004.09.007</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.schres.2004.09.007</ArticleId>
            <ArticleId IdType="pubmed">15531405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott T, Nieder A (2019) Dopamine and cognitive control in prefrontal cortex. Trends Cogn Sci 23(3):213–234. https://doi.org/10.1016/j.tics.2018.12.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tics.2018.12.006</ArticleId>
            <ArticleId IdType="pubmed">30711326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearlson GD (2000) Neurobiology of schizophrenia. Ann Neurol 48:556–566. https://doi.org/10.1002/1531-8249(200010)48:4%3c556:AID-ANA2%3e3.0.CO;2-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200010)48:4&lt;556:AID-ANA2&gt;3.0.CO;2-2</ArticleId>
            <ArticleId IdType="pubmed">11026439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pietraszek M, Michaluk J, Romańska I, Wąsik A, Gołembiowska K, Antkiewicz-Michaluk L (2009) 1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse Inhibition, and impairment of working memory in rat. Neurotox Res 16:390–407. https://doi.org/10.1007/s12640-009-9097-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12640-009-9097-y</ArticleId>
            <ArticleId IdType="pubmed">19649683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Preissmann D, Dépré M, Schenk F, Gisquet-Verrier P (2016) Anxiety modulates cognitive deficits in a perinatal glutathione deficit animal model of schizophrenia. Brain Res 1648:459–468. https://doi.org/10.1016/jbrainres.2016.07.042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/jbrainres.2016.07.042</ArticleId>
            <ArticleId IdType="pubmed">27485658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapoport JL, Gogtay N (2011) Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci 29:251–258. https://doi.org/10.1016/j.ijdevneu.2010.10.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijdevneu.2010.10.003</ArticleId>
            <ArticleId IdType="pubmed">20955775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rougemont M, Do KQ, Castagné V (2002) New model of glutathione deficit during development: effect on lipid peroxidation in the rat brain. J Neurosci Res 70:774–783. https://doi.org/10.1002/jnr.10439</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.10439</ArticleId>
            <ArticleId IdType="pubmed">12444599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savransky A, Chiappelli J, Du X, Carino K, Kvarta M, Bruce H, Kochunov P, Goldwaser E, Tan Y, Hare S, Hong LE (2021) Association of working memory and elevated overnight urinary norepinephrine in patients with schizophrenia. J Psychiatr Res 137:89–95. https://doi.org/10.1016/j.jpsychires.2021.02.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpsychires.2021.02.005</ArticleId>
            <ArticleId IdType="pubmed">33662656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol (Berl). 124(1-2):57-73. https://doi.org/10.1007/BF02245606</Citation>
        </Reference>
        <Reference>
          <Citation>Stone JM, Morrison PD, Pilowsky LS (2007) Glutamate and dopamine dysregulation in schizophrenia – a synthesis and selective review. J Psychopharmacol 21:440–452. https://doi.org/10.1177/0269881106073126</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881106073126</ArticleId>
            <ArticleId IdType="pubmed">17259207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994a) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139–154</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpsyc.1994.03950020063007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuitry of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156:194–215</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s002130100799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swerdlow NR, Keith VA, Braff DL, Geyer MA (1991) Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 256:530–536</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1825226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swerdlow NR, Zisook D, Taaid N (1994b) Seroquel (ICI 204, 636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: similarities to clozapine. Psychopharmacology 114:675–678</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02245001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamminga CA, Holcomb HH (2005) Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 10:27–39</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mp.4001563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Os J, Rutten BP, Poulton R (2008) Gene-environment interaction in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 34:1066–1082. https://doi.org/10.1093//schbul/sbn117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093//schbul/sbn117</ArticleId>
            <ArticleId IdType="pubmed">18791076</ArticleId>
            <ArticleId IdType="pmc">2632485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wąsik A, Białoń M, Antkiewicz-Michaluk L (2019) Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment. Pharmacol Biochem Behav 181:17–27. https://doi.org/10.1016/j.pbb.2019.04.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pbb.2019.04.002</ArticleId>
            <ArticleId IdType="pubmed">30965047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wędzony K, Fijał K, Maćkowiak M, Chocyk A, Zajączkowski W (2008) Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia. Neuroscience 60:856–864</Citation>
        </Reference>
        <Reference>
          <Citation>Wędzony K, Maćkowiak M, Zajaczkowski W, Fijał K, Chocyk A, Czyrak A (2000) WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23(5):547–559. https://doi.org/10.1016/S0893-133X(00)00150-0 . PMID: 11027920</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0893-133X(00)00150-0</ArticleId>
            <ArticleId IdType="pubmed">11027920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL (2007) Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 95:134–142</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.schres.2007.05.039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao JK, Keshavan MS (2011) Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 15:2011–2035. https://doi.org/10.1089/ars.2010.3603</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2010.3603</ArticleId>
            <ArticleId IdType="pubmed">21126177</ArticleId>
            <ArticleId IdType="pmc">3159108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao JK, Leonard S, Reddy R (2006) Altered glutathione redox state in schizophrenia. Dis Markers 22:83–93. https://doi.org/10.1155/2006/248387</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2006/248387</ArticleId>
            <ArticleId IdType="pubmed">16410648</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
